摘要
目的研究阿立哌唑在治疗精神分裂症中的应用价值分析。方法选取该院2013年2月—2014年6月间收治的精神分裂症患者96例,随机分为对照组和实验组。对照组给予利培酮治疗,实验组给予阿立哌唑治疗;对治疗前及治疗后8周用阳性和阴性症状量表(PANSS)以及(TESS)量表观察对比两组临床疗效及不良反应情况。结果实验组治疗后总有效率为89.5%,对照组总有效率为87.5%,两组间比较差异无统计学意义(P>0.05);治疗后两组患者PANSS评分均较治疗前差异有统计学意义(P<0.05),且实验组不良反应较对照组少。结论对于精神分裂症的治疗,阿立哌唑和利培酮均有的疗效,但阿立哌唑不良反应较少,安全性更好。
Objective To study the application value analysis of aripiprazole in the treatment of schizophrenia. Methods 96 cases with schizophrenia admitted in our hospital from February 2013 to June 2014 were selected and divided into the control group and the experimental group. The control group was given risperidone for treatment, and the experimental group was given aripiprazole.The clinical efficacy and adverse reactions evaluated by Positive and Negative Syndrome Scale（PANSS） and Treatment Emergent Symptom Scale（TESS） before treatment and 8 weeks after treatment were observed and compared between the two groups. Results After treatment, the total effective rate of the experimental group was 89.5%, and that of the control group was 87.5%, there was no significant difference between the two groups（P〉0.05）; PANSS score were improved in two groups compared to those before treatment（P〈0.05）; but the adverse reactions of the experimental group were less than those of the control group. Conclusion For the treatment of schizophrenia, both aripiprazole and risperidone are effective, but aripiprazole has less adverse reactions and better security.
出处
《中外医疗》
2014年第32期1-2,共2页
China & Foreign Medical Treatment
